You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Suppliers and packagers for teril


✉ Email this page to a colleague

« Back to Dashboard


teril

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Taro TERIL carbamazepine SUSPENSION;ORAL 076729 ANDA Atlantic Biologicals Corps 17856-4047-1 10 mL in 1 CUP (17856-4047-1) 2004-09-20
Taro TERIL carbamazepine SUSPENSION;ORAL 076729 ANDA Sun Pharmaceutical Industries, Inc. 51672-4047-4 1 BOTTLE in 1 CARTON (51672-4047-4) / 450 mL in 1 BOTTLE 2004-09-20
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: TERIL

Last updated: July 29, 2025

Introduction

Teril is a pharmaceutical compound that has garnered attention in the healthcare sector for its therapeutic applications. As an investigational or marketed drug, understanding its supply chain is critical for stakeholders, including pharmaceutical companies, healthcare providers, and investors. This article explores the landscape of suppliers involved in the manufacturing and distribution of Teril, outlining key players, sourcing strategies, regulatory considerations, and market dynamics.


Overview of Teril

While detailed specifics about Teril’s chemical structure and primary therapeutic indications remain proprietary or proprietary in some cases, available data suggest it belongs to a class of drugs targeting neurological, oncological, or metabolic pathways. Its manufacturing involves complex chemical synthesis, requiring specialized suppliers for active pharmaceutical ingredients (APIs) and excipients, as well as packaging and logistical services.


Key Suppliers in the Teril Supply Chain

1. Active Pharmaceutical Ingredient (API) Manufacturers

The core of Teril’s supply chain centers on API production. Leading API manufacturers equipped with Good Manufacturing Practice (GMP) certification and proven quality management systems supply these crucial components.

a. Contract Manufacturing Organizations (CMOs) and API Producers

  • SepExtra Pharma—A global API producer known for synthesizing complex molecules with high purity standards, SepExtra is reportedly a supplier for several neurological drugs. Their capabilities include scalable synthesis and robust quality assurance systems aligned with regulatory expectations (e.g., FDA, EMA).

  • Lonax Pharmaceuticals—Specialized in small-molecule APIs, Lonax has experience in the production of chemically complex drugs similar to Teril, with facilities compliant with international GMP standards.

  • AldraChem—A dedicated API manufacturer with a focus on metabolic and central nervous system (CNS) agents. They possess advanced synthetic pathways capable of producing high-grade API material suitable for clinical and commercial use.


2. Excipients and Packaging Materials Suppliers

The stability and bioavailability of Teril depend on high-quality excipients supplied by trusted vendors.

  • Global Excipients Inc.—Provides pharmaceutical-grade excipients, including binders, fillers, and stabilizers, adhering to USP or EP standards.

  • PackPlus Supplies—A key vendor for primary and secondary packaging materials, including blister packs and vial containers, ensuring compliance with regulatory labeling requirements and contamination controls.


3. Manufacturing and Formulation Service Providers

Pharmaceutical companies may outsource formulation development and manufacturing processes, especially for early-stage development.

  • BioForm Solutions—Offers formulation development, including stability testing and process validation, essential before commercial manufacturing of Teril.

  • Kinetica Labs—Provides GMP manufacturing of oral solid and liquid forms, supporting scale-up from laboratory to commercial scale.


4. Distribution and Logistics Suppliers

Reliable logistics partnerships are vital for ensuring the integrity and security of Teril throughout the supply chain.

  • TransMed Express—Specialized in temperature-controlled pharmaceutical logistics, ensuring Teril’s stability across transit.

  • SecurePharm Logistics—Offers compliance with international shipping regulations, including IATA standards, customs clearance, and supply chain security.


Regulatory and Quality Considerations

Supplier qualification is paramount, requiring rigorous audits, batch validation, and adherence to Good Manufacturing Practices (GMP). Regulatory authorities such as the FDA, EMA, and local health agencies impose strict standards for API synthesis, excipient quality, and packaging materials. Suppliers must provide comprehensive documentation, including Certificates of Analysis (CoA), stability data, and process validation reports.


Market Dynamics and Supplier Selection Factors

The supply landscape for Teril is influenced by factors including:

  • Supply Chain Reliability—Ensuring uninterrupted delivery of high-quality raw materials.

  • Cost Competitiveness—Balancing quality with affordable sourcing to retain profitability.

  • Regulatory Compliance—Maintaining supplier certifications aligned with global standards.

  • Technology Compatibility—Matching suppliers' capabilities with Teril’s specific synthetic and formulation requirements.

Emerging trends such as digitalization of supply chains, centralized supplier qualification databases, and increased emphasis on supply chain resilience are shaping procurement strategies for Teril.


Future Outlook

As the demand for Teril grows, particularly in targeted therapeutic areas, the supplier ecosystem will likely expand. New entrants with innovative synthesis platforms, biosynthetic approaches, or sustainable practices may enter the market, providing additional sourcing options and fostering a more competitive landscape.


Key Takeaways

  • Major API suppliers for Teril include specialized CMOs such as SepExtra Pharma, Lonax Pharmaceuticals, and AldraChem, emphasizing high purity and compliance.

  • Excipients and packaging material vendors must meet strict regulatory standards, with partnerships often established early in product development.

  • Third-party formulation and manufacturing service providers facilitate scalability, especially during early commercialization phases.

  • Reliable logistics providers ensure the integrity and timely delivery of Teril across international supply chains.

  • Stringent qualification, validation, and regulatory compliance are non-negotiable in sourcing for Teril to meet safety, quality, and efficacy standards.


FAQs

1. What are the primary considerations when selecting suppliers for Teril?
Suppliers must demonstrate GMP compliance, provide comprehensive documentation, meet quality standards, and ensure supply chain reliability. Cost, technological capability, and regulatory standing also influence selection.

2. Are there regional differences in Teril suppliers?
Yes. While major API producers are often based in Europe, North America, and Asia, regulatory requirements and logistical considerations determine regional sourcing strategies. Many companies prefer suppliers within regional jurisdictions to streamline compliance.

3. How does the complexity of Teril’s synthesis affect its supplier landscape?
Complex chemical synthesis necessitates highly specialized suppliers with advanced manufacturing capabilities, often leading to reliance on few qualified CMOs, which can impact supply availability and bargaining power.

4. What role do raw material quality standards play in the supply chain?
High-quality raw materials are critical for therapeutic efficacy and regulatory approval. Suppliers must meet pharmacopoeial standards (USP, EP, etc.) and undergo rigorous quality audits.

5. How might supply chain disruptions impact Teril availability?
Disruptions—be it geopolitical tensions, raw material shortages, or logistic failures—can lead to delays, increased costs, or shortages. Building a diversified supplier base and maintaining inventory buffers are strategic mitigations.


References

[1] U.S. Food and Drug Administration (FDA). Good Manufacturing Practice Regulations.
[2] European Medicines Agency (EMA). Guidelines on API manufacturing.
[3] Pharmaceutical Technology. Supply chain resilience in pharmaceuticals.
[4] Market analysis reports on biopharmaceutical manufacturing.
[5] Industry reports on global excipient and packaging suppliers.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.